1913O Results from the registrational phase I/II ARROW...

Annals of Oncology 2020 / 09 Vol. 31

1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Hu, M., Subbiah, V., Wirth, L.J., Schuler, M., Mansfield, A.S., Brose, M.S., Curigliano, G., Leboulleux, S., Zhu, V.W., Keam, B., Matos, I., Lin, C-C., Adkins, D., Baik, C.S., Lopes, G., Godbert, Y.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.1401
Date:
September, 2020
File:
PDF, 136 KB
2020
Conversion to is in progress
Conversion to is failed